Sunitinib for the treatment of gastrointestinal stromal tumours

  • Technology appraisal guidance
  • TA179
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the committee

The evidence review group (ERG) report for this appraisal was prepared by Peninsula Technology Assessment Group (PenTAG):

  • Bond M, et al. (2009) The clinical and cost effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). The manufacturer/sponsor was also invited to make written submissions. The professional/specialist and patient/carer groups and other consultees had the opportunity to give their expert views and, along with the manufacturer/sponsor, also have the opportunity to appeal against the final appraisal determination.

  • Manufacturer/sponsor:

    • Pfizer (sunitinib)

  • Professional/specialist and patient/carer groups:

    • Association of Upper GI Surgeons

    • Rarer Cancers Forum

    • Royal College of Nursing

    • Royal College of Pathologists

    • Royal College of Physicians, Medical Oncology Joint Special Committee

    • Royal College of Radiologists

    • Sarcoma UK

  • Other consultees

    • Department of Health

    • Plymouth Teaching PCT

    • Welsh Assembly Government

  • Commentator organisations (did not provide written evidence and without the right of appeal)

    • Department of Health, Social Services and Public Safety for Northern Ireland

    • National Collaborating Centre for Cancer

    • NHS Quality Improvement Scotland

    • Peninsula Technology Assessment Group, University of Exeter (PenTAG)

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on sunitinib by attending the initial committee discussion and providing written evidence to the committee. They are invited to comment on the ACD.

  • Professor Ian Judson, nominated by Royal College of Physicians – clinical specialist

  • Professor Marco Novelli, nominated by Royal College of Pathologists

  • Ms Stella Pendleton, nominated by Rarer Cancers Forum – patient expert

  • Mrs Judith Robinson, nominated by GIST Support UK – patient expert.